Ipsos sells market research and consumer insight, from survey panels and brand tracking studies to its data-science and advisory services, mostly to consumer goods and media clients. Its moat rests on proprietary panels and long-running tracking datasets that are costly to replicate and sticky once embedded in a client's planning cycle. Revenue growth has stalled at 1.3%, so the case rests on margin and cash generation rather than top-line momentum, and an 8.5% operating margin against a 67.5% gross margin shows where the upside would come from if costs are reined in. At 9.3 times trailing and 6.6 times forward earnings, with an 11.9% ROE, the market is pricing in little recovery. The question for a deeper look is whether the operating margin can expand while growth holds positive, since that would close much of the gap to the multiple.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 11:04 CEST | Fair value | €60.49 | first publication | €37.38 |
| 23 Oct 2026, 11:04 CEST | Rating | Undervalued | first publication | €37.38 |
| 23 Oct 2026, 01:53 CEST | ACCE price target | €48.00 | first publication | €37.38 |
Answered from Ipsos SA fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| IPS.PA Ipsos SA | €35.30 | €60 | 42% below | 8.8x | 11.9% | 67 | 62 |
| ICFI ICF International Inc. Common Stock | $94.40 | $106 | 11% below | 18.8x | 8.6% | 56 | 63 |
| CRAI CRA International Inc. Common Stock | $200.14 | $140 | 43% above | 26.8x | 26.0% | 74 | 70 |
| HURN Huron Consulting Group Inc. Common Stock | $195.69 | $146 | 34% above | 28.0x | 26.9% | 69 | 77 |
| FCN FTI Consulting Inc. Common Stock | $157.24 | $166 | 5% below | 18.9x | 15.6% | 64 | 50 |
| SBC SBC Medical Group Holdings Incorporated Common Stock | $5.28 | $6 | 18% below | 11.2x | 18.9% | 95 | 89 |
| BTS-B.ST BTS Group AB (publ) | kr 231.00 | - | - | 47.2x | 6.3% | 60 | 61 |
Where IPS.PA ranks against its sector peers on each metric.